首页> 外文OA文献 >Early nasogastric tube feeding in optimising treatment for hyperemesis gravidarum: The MOTHER randomised controlled trial (Maternal and Offspring outcomes after Treatment of HyperEmesis by Refeeding)
【2h】

Early nasogastric tube feeding in optimising treatment for hyperemesis gravidarum: The MOTHER randomised controlled trial (Maternal and Offspring outcomes after Treatment of HyperEmesis by Refeeding)

机译:早期鼻胃管饲喂可改善妊娠呕吐的最佳治疗方法:MOTHER随机对照试验(通过再次饲喂治疗超呕吐的母亲和后代结局)

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

textabstractBackground: Hyperemesis gravidarum (HG), or intractable vomiting during pregnancy, is the single most frequent cause of hospital admission in early pregnancy. HG has a major impact on maternal quality of life and has repeatedly been associated with poor pregnancy outcome such as low birth weight. Currently, women with HG are admitted to hospital for intravenous fluid replacement, without receiving specific nutritional attention. Nasogastric tube feeding is sometimes used as last resort treatment. At present no randomised trials on dietary or rehydration interventions have been performed. Small observational studies indicate that enteral tube feeding may have the ability to effectively treat dehydration and malnutrition and alleviate nausea and vomiting symptoms. We aim to evaluate the effectiveness of early enteral tube feeding in addition to standard care on nausea and vomiting symptoms and pregnancy outcomes in HG patients. Methods/Design: The MOTHER trial is a multicentre open label randomised controlled trial ( www.studies-obsgyn.nl/mother ). Women ≥ 18 years hospitalised for HG between 5 + 0 and 19 + 6 weeks gestation are eligible for participation. After informed consent participants are randomly allocated to standard care with intravenous rehydration or early enteral tube feeding in addition to standard care. All women keep a weekly diary to record symptoms and dietary intake until 20 weeks gestation. The primary outcome will be neonatal birth weight. Secondary outcomes will be the 24-h Pregnancy Unique Quantification of Emesis and nausea score (PUQE-24), maternal weight gain, dietary intake, duration of hospital stay, number of readmissions, quality of life and side-effects. Also gestational age at birth, placental weight, umbilical cord plasma lipid concentration and neonatal morbidity will be evaluated. Analysis will be according to the intention to treat principle. Discussion: With this trial we aim to clarify whether early enteral tube feeding is more effective in treating HG than intravenous rehydration alone and improves pregnancy outcome. Trial registration: Trial registration number: NTR4197. Date of registration: October 2nd 2013.
机译:妊娠期呕吐(HG)或妊娠期顽固性呕吐是妊娠早期住院的最常见原因。 HG对产妇的生活质量有重大影响,并多次与不良的妊娠结局(如低体重)联系在一起。目前,患有HG的妇女被送往医院接受静脉补液,而没有受到特别的营养关注。有时将鼻胃管喂养用作最后的治疗方法。目前,尚无关于饮食或补液干预措施的随机试验。小型观察研究表明,肠内饲管可能具有有效治疗脱水和营养不良并减轻恶心和呕吐症状的能力。我们的目标是评估除HG病人的恶心和呕吐症状以及妊娠结局的标准护理外,还评估早期肠内输注的有效性。方法/设计:MOTHER试验是一项多中心开放标签随机对照试验(www.studies-obsgyn.nl/mother)。 ≥18岁的孕妇因妊娠5 + 0至19 + 6周而住院,有资格参加。知情同意后,除标准护理外,还随机将参与者分配至静脉补液或早期肠内饲喂的标准护理。所有妇女每周都要记录日记,以记录症状和饮食摄入,直到妊娠20周为止。主要结局是新生儿出生体重。次要结果将是24小时妊娠呕吐和恶心评分(PUQE-24),孕妇体重增加,饮食摄入,住院时间,再入院次数,生活质量和副作用。还将评估出生时的胎龄,胎盘重量,脐带血浆脂质浓度和新生儿发病率。分析将根据意图对待原则进行。讨论:通过该试验,我们旨在阐明早期肠内饲管喂养是否比单纯静脉补液更有效地治疗HG,并改善妊娠结局。试用注册:试用注册号:NTR4197。注册日期:2013年10月2日。

相似文献

  • 外文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号